Attached files
| file | filename |
|---|---|
| EX-10.1 - INVESTOR RELATIONS CONSULTING AGREEMENT - CALECO PHARMA CORP. | exhibit10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 10, 2011
Date of Report (Date of earliest
event reported)
CALECO PHARMA
CORP.
(Exact name of registrant as specified in its
charter)
| NEVADA | 000-51261 | 20-1147435 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer Identification No.) |
| incorporation) |
| 59 East Mall Road | |
| Building 4, Suite 201 | |
| Long Valley, NJ | 07853 |
| (Address of principal executive offices) | (Zip Code) |
(908) 752-4240
Registrant's telephone number,
including area code
Not Applicable
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
SECTION 1 – REGISTRANT’S BUSINESS AND OPERATIONS
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
Investor Relations Consulting Agreement
On May 10, 2011, Caleco Pharma Corp. (the “Company”) entered into an investor relations consulting agreement (the “Agreement”) with Institutional Analysts Inc. (“IA”) whereby IA will provide investor relations consulting services to the Company. IA will provide services including, but not limited to, ongoing research and reports, newsletter distribution, introductions to brokers and counseling on the style and content of investor relations materials. The Agreement is for a one year term ending May 9, 2012. As compensation for IA’s services, the Company has agreed to:
| (a) |
pay $10,000 to IA as follows: |
| (i) |
$2,500 on execution of the Agreement; | |
| (ii) |
$2,500 on or before September 10, 2011; | |
| (iii) |
$2,500 on or before February 10, 2012; and | |
| (iv) |
$2,500 on or before May 10, 2012; and |
| (b) |
issue 2,000,000 shares of the Company’s common stock to IA on execution of the Agreement. |
The issuance of shares was completed pursuant to the provisions of Rule 506 of Regulation D of the Securities Act of 1933, as amended. IA represented that was an accredited investor as defined under Regulation D.
The above summary is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| Exhibit Number | Description of Exhibit | |
| 10.1 | Investor Relations Consulting Agreement between the Company and Institutional Analyst, Inc. dated May 10, 2011 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CALECO PHARMA CORP. | ||
| Date: May 16, 2011 | ||
| By: | /s/ John Boschert | |
| JOHN BOSCHERT | ||
| Chief Executive Officer, President, | ||
| Secretary & Treasurer |
2